

CURRICULUM VITAE

Professor Shabir Ahmed Madhi

Date of Birth: 28 November 1966
Nationality: South African
Curent Position/s held:
2008 to date Professor of Vaccinology; School of Pathology, University of the Witwatersrand
2008 to date South African Research Chair Department of Science and Technology, National Research Foundation, Vaccine Preventable Diseases.
2017 to date Co-director: African Leadership in Vaccinology Expertise.
2020 to date Director: University of Witwatersrand /South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit.
2021 to date Dean: Faculty of Health Sciences, University of the Witwatersrand

Past Positions

2013 to March 2020 Director: University of Witwatersrand /Medical Research Council Respiratory and Meningeal Pathogens Research Unit.
2011 to Sept 2017 Executive Director: National Institute for Communicable Diseases; South Africa Service
February 2017 to Sept 2017 Acting Chief Executive Officer; National Health Laboratory Services, Sandringham, South Africa
2007 to 2013 Co-Director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013)
2003 to 2010 Associate Professor Hubert Dept. of Global Health; Rollins School of Public Health, Emory University, Atlanta, GA, USA
2001 to 2008 Senior Medical Researcher, Wits Health Consortium (RMPRU); University of the Witwatersrand, Johannesburg, South Africa
1997 to 2008 Consultant in Intensive Care Unit, Chris Hani Baragwanath Academic Hospital, Soweto, South Africa.
1997 to 2007 Honorary Consultant: Department of Paediatrics, Chris Hani Baragwanath Academic Hospital.
1997 to 2000 Senior Research Officer, National Health Laboratory Services, Respiratory and Meningeal Pathogens Research Unit; Braamfontein, South Africa
1993 to 1996 Registrar in Paediatrics, Department of Paediatrics, University of the Witwatersrand, Johannesburg, South Africa.
1992 Senior Medical Officer, Department of Paediatrics, Johannesburg Hospital, Johannesburg, South Africa.
1991 Medical Officer (Internship), Chris Hani Baragwanath Academic Hospital; Soweto, South Africa

TERTIARY QUALIFICATIONS

2010:	Sub-speciality registration – Infectious Diseases. Health Professional Council of South Africa
2003:	PhD (Health Sciences); University of the Witwatersrand, Johannesburg, South Africa.
2001-2010:	Sub-speciality registration - Critical Care Paediatrics. Health Professional Council of South Africa
1998:	Masters in Medicine (MMed Paediatrics); University of the Witwatersrand, Johannesburg
1996:	Fellow College of Paediatrics (FCPaeds (SA); College of Medicine, South Africa
1990:	Bachelor of Medicine and Bachelor of Surgery (MBBCh); University of the Witwatersrand, Johannesburg, South Africa

MEMBERSHIP OF PROFESSIONAL BODIES / ASSOCIATIONS

Jan 2019 to date	Member: WHO Strategic Advisory Group of Experts (Vaccines).
Feb 2018 to date	Chair National Advisory Group for Immunization, South Africa
2017 to date	Member: The World Academy of Sciences (TWAS)
2016 to date	Member Royal Society of South Africa
Aug 2016 to date	Medical Scientific Advisory Committee: Global Pneumonia Prevention Coalition
2014 to 2018	Board Member: World Association for Infectious Diseases and Immunological Disorder (WAidid)
2013 to 2017	Chair: International Scientific Committee of World Society of Paediatric Infectious Diseases
2013 to date	International Scientific Committee Member of International Society of Infectious Diseases (2013-Current)
2013 to 2018	Deputy Chair: National Advisory Group for Immunization, South Africa
2012 to date	Member: Academy of Sciences of South Africa
2009 to 2017	Board Member: International Symposium for Pneumococci and Pneumococcal Diseases
2010 – 2013	President: World Society of Paediatric Infectious Diseases
2009	Board-member: World Society of Paediatric Infectious Diseases
2008 – 2013	Board member: International Scientific Committee – World Society of Paediatric Infectious Diseases
2008 – 2013	Deputy-president: Southern African Society of Infectious Diseases
2003 to date	Member: European Society of Paediatric Infectious Diseases (2003-)
2002 to date	Member: Federation of Infectious Diseases Society of South Africa.
2002 – 2009	Member: Critical Care Society of South Africa. (2002-2009)
1997 to date	Member: South African Paediatric Association (1997-)

1997 to date	Fellow: College of Medicine, South Africa (1997-)
1996 to date	Member: South African Medical Association (1996-)

HONOURS, AWARDS AND RECOGNITIONS

2017:	Elected as Member of The World Academy of Sciences (TWAS)
2016:	National Research Foundation A2 rating
2016:	Elected as Member of Royal Society of South Africa
2016:	European & Developing Countries Clinical Trial Partnership: 2016 award for Scientific Leadership
2015:	Guest Speaker: Faculty of Health Sciences Graduation Ceremony; December 2015.
2013:	Medical Research Council: Life Time Achievement Award (Platinum Medal)
2012:	Elected Member to Academy of Science of South Africa (ASSAF)
2011:	National Research Foundation A2 rating.
2010:	Vice-Chancellors Award for Research. University of the Witwatersrand.
2010:	NRF President's Award for: Transformation of the Science Cohort.
2009:	National Science and Technology Forum: TW Kambule Award: Senior Black Researcher over the past 5-10 years.
2009:	Special Fellowship Award- Past Alumni Invite to Celebrate the 10 th Anniversary of the Advanced Vaccinology Course; Annecy; France May 22-25 th 2009
2006:	European Society for Infectious Diseases, Young Investigators Award.
2004:	University of the Witwatersrand, Faculty Research Prize for best Research Article.
2001:	Watkins-Pitchford prize. Award Re: Best contribution to the literature during the year 2000 by a member of the South African Institute for Medical Research staff of less than 10-year standing.
2020:	Harry Oppenheimer Foundation Fellowship Award
2021:	Academy of Science of South Africa (ASSAF) Science-for-Society Gold Medal
2021:	Apolitical's 100 most influential academics in Government of COVID-19 response (listed as one of five South African scientists).

NATIONAL RESEARCH FOUNDATION RATING

2017-current	Category A2 (Internationally Recognised Leader in field of research as evaluated by peers; Effective 2017)
2011 to 2016	Category A2 (Internationally Recognised Leader in field of research as evaluated by peers)

OTHER INTERNATIONAL TEMPORARY APPOINTMENTS CONSULTANCIES

2019- ongoing	Member WHO Strategic Advisory Group of Experts (SAGE)
2018-ongoing	WHO Strategic advisory group: Group B streptococcus value proposition
2018-ongoing	WHO working group: Influenza vaccination of health workers.

2018 -ongoing Member WHO Product Development Vaccine

2017: Invited participant: WHO Product Development Vaccine Meeting, 22-23 June 2017, Geneva, Switzerland.

2016: Chair: Eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses. August 23 and 24, 2016 Sheraton Chicago Hotel and Towers, Chicago, USA.

2016: Invited participant: WHO Consultation on Maternal RSV Vaccine Development, 25 to 26 April 2016, Geneva, Switzerland.

2016: Chair (and speaker): WHO Consultation on GBS Vaccine Development, 27 to 28 April 2016, Geneva, Switzerland.

2016: Invited participant/panellist: WHO/BMGF: Global vaccine and Immunization Forum (GVIR): Panellist: New technologies to support measles elimination.. March 15-17 2016, Johannesburg , South Africa.

2015: WHO Temporary Consultant: Technical consultation on maternal influenza immunization evidence and implementation. 25-26 March 2015, Geneva, Switzerland.

2015: Co-Chair Scientific Advisory Group: A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa.

2014: Board Member: Data Safety Monitoring Board – A Phase Ib, Dose-Escalating, Safety and Immunogenicity trial of the novel monovalent Ebola Zaire candidate vaccine, cAd3-EBO Z in Malian adults aged 18-50 years.”

2013: Participant. Measuring short and long-term vaccine impact of PCV. World Health Organisation. Crowne Plaza Hotel, in Geneva, Switzerland. 16-19 September, 2013.

2013: Advisor: RSV Vaccines for Maternal Immunization. PATH. 11 July 2013. Washington DC.

2013 to date Member: Bill and Melinda Gates Foundation: Global Health Program Scientific Advisory Committee.

2012: Temporary consultant: Optimizing rotavirus immunization schedules. WHO Ad Hoc Expert Consultation on Rotavirus Vaccination Schedules. 13-14 February 2012. WHO, Geneva.

2011 to date Member CAPRISA Scientific Advisory Board (South Africa)

2010-2011: Member: Scientific Monitoring Board: HIV Vaccine Trials Network (HVTN)

2011: Invited participant: Bill and Melinda Gates Foundation: Maternal Influenza Immunization: Evidence, Policy Consideration, and Action Plan Convening Gates. 1-3 June 2011. Hyatt Regency London; London.

2009-2010: Technical advisor/Consultant: Pneumonia Etiology Research for Child Health (PERCH); Johns Hopkins Bloomberg School of Public Health. 8-10th Sep 2009; Washington DC, USA.

- 2009: Temporary Consultant World Health Organisation: meeting to review WHO recommendations for the management of diarrhoea and pneumonia in the context of HIV infection in infants and children. 19-21 October, 2009; Geneva, Switzerland.
- 2009 Advisor: Supporting National Independent Immunization and Vaccine Advisory Committees: The SIVAC Initiative. 29th May 2009; Paris; France
- 2008: Faculty Member: Global Masterclass on Childhood Bacterial Respiratory Diseases. (Brussels; Belgium: 29-30th March 2008)
- 2008: Technical Advisor: GAVI PneumoADIP (Rome, Italy: 10-11th March 2008)
- 2008: Temporary consultant WHO. Global Action Plan for Pneumonia. (Geneva, Switzerland: 25-27th February 2008).
- 2008: Invited participant: Global Burden of Disease: Respiratory syncytial virus. (Edinburgh, Scotland: 28-29th January 2008).
- 2007: Consultant/Faculty: Physicians Academy for Clinical and Management Excellence. 1st Pneumonia Working Group Conference. (Seoul; South Korea. 14-15th December 2007).
- 2007: Invited Participant (African Representative): Global Vaccine Safety Datanet Meeting (Annecy, France: 11-13th Sept 2007)
- 2007: Temporary consultant to Gates Foundation: Pneumonia Consultation Meeting. (Seattle USA, 3-6th May 2007)
- 2007: Temporary consultant to WHO: Global Action Plan for Pneumonia (La Mainaz France, 3rd-5th March 2007)
- 2006: Temporary consultant to NIH/NIAID: WHO Essential care and Prevention Meeting (Switzerland).
- 2005: Technical advisor: Introduction of Pneumococcal Conjugate Vaccine Use in Developing Countries. GAVI PneumoADIP (London; United Kingdom).
- 2003: Technical advisor: Activities in Research and Development Necessary to Accelerate the Introduction of Pneumococcal Conjugate Vaccine Use in Developing Countries. GAVI PneumoADIP.
- 2003: Temporary Consultant to World Health Organisation: "*Haemophilus influenzae* type b prevention in Sub-Saharan Africa"
- 2003: Temporary Consultant to World Health Organisation: Reviewer of proposal for: "Alternate Schedules for Introducing the Pneumococcal Conjugate Vaccine into Developing Countries".
- 2003: Temporary Consultant to World Health Organisation: Management of Acute Respiratory Tract Infections in Countries with a high Prevalence of HIV-1 Infection.
- 2001: International Faculty member of the "Global Health Course" program initiated by Department of Health, Finland.
- 1998-2001: Temporary Consultant to World Health Organisation "Respiratory syncytial virus in developing countries" working group.

1998-2001: Temporary Consultant to World Health Organisation pneumonia-radiology working-group.

SUPERVISION OF HIGHER DEGREES (EXCLUDING POST-DOCS)

- **PRIMARY SUPERVISOR OF MMed DEGREES AWARDED**

- 2001 Dr D Ruffini, University of the Witwatersrand**
MMed Dissertation:
- 2001 Dr M Htay, University of the Witwatersrand**
MMed Dissertation:
- 2004 Dr G Sorour, University of the Witwatersrand**
MMed Thesis: The response of natural RSV infection in HIV-infected children compared to the HIV-uninfected children
- 2004 Dr C Ngwazi, University of the Witwatersrand**
MMed Dissertation:
- 2008 Dr D Moore, University of the Witwatersrand**
MMed Dissertation: Defining the burden of pulmonary tuberculosis and probing the prevalence of pneumococcal bacterial co-infections among children hospitalised with pulmonary tuberculosis that were enrolled in a pneumococcal vaccine trial
- 2012 Dr Z Dangor, University of the Witwatersrand**
MMed Dissertation: A time-series analysis on the impact of the antiretroviral treatment program on the burden of hospitalization for culture-confirmed mycobacterium tuberculosis in Sowetan children
- 2014 Dr M Haupfleisch, University of the Witwatersrand**
MMed Dissertation: The impact of routine pneumococcal conjugate immunization on bacterial meningitis in Sowetan children - A time-series analysis
- 2014 Dr S Chaya, University of the Witwatersrand**
MMed Dissertation: Epidemiology of tuberculosis meningitis in an area with a high prevalence of HIV-infection
- 2015 Dr V Mammed, University of the Witwatersrand**
MMed Dissertation: Impact of the pneumococcal conjugate vaccine on culture-confined pulmonary tuberculosis in hospitalized children

- **PRIMARY SUPERVISOR OF MSc DEGREES AWARDED**

- 2011 Dr Z Ditse, University of the Witwatersrand**
MSc Dissertation: The effect of natural colonization by streptococcus pneumoniae, on the systemic and mucosal immune responses to common pneumococcal antigens with immune protective potential
- 2011 Dr Z Radebe, University of the Witwatersrand**
MSc Dissertation: Clinical epidemiology of newly discovered respiratory viruses
- 2001 Ms Z Makhari, University of the Witwatersrand**
MSc Dissertation: Characterization of bacterial causes of diarrhoea in an under-five population in South Africa
- 2018 Ms B Smith, University of the Witwatersrand**
MSc Dissertation: Determining sequence type of circulating bordetella pertussis strains isolated from South African infants
- 2018 Ms M Monthla, University of the Witwatersrand**
MSc Dissertation: Association between cytokine profile and disease severity in children infected with respiratory syncytial virus causing lower respiratory tract infection
- 2020 Mr B Mahlangu, University of the Witwatersrand**
MSc Dissertation: Identification of virulence genes from non-typeable Haemophilus influenzae isolates recovered from pneumonia cases and community controls
- Current Ms Palesa Morailane, University of the Witwatersrand**
Surveillance of Streptococcus pneumoniae in rural South African children and their caregivers during the era of childhood pneumococcal vaccination.

- **PRIMARY SUPERVISOR OF PhD DEGREES AWARDED**

- 2007 **Dr H Ludick, University of the Witwatersrand**
PhD Thesis: Clinical and molecular epidemiology of human metapneumovirus
- 2013 **Dr M Mhlongo, University of the Witwatersrand**
PhD Thesis: Animal model on pneumococcal colonization
- 2013 **Dr M Madzivhandila, University of the Witwatersrand**
PhD Thesis: Serotype, pilus island distribution and molecular epidemiology of streptococcus agalactiae isolates from colonisation and invasive disease
- 2014 **Dr C Cohen, University of the Witwatersrand (Awarded Faculty Prestigious Post-graduate award 2015)**
PhD Thesis: Influenza-associated morbidity and mortality in South Africa
- 2015 **Dr S Nzenze, University of the Witwatersrand**
PhD Thesis: Effect of the introduction of pneumococcal conjugate vaccine on the epidemiology of pneumococcal nasopharyngeal carriage in South African children and adults.
- 2015 **Dr Z Dangor, University of the Witwatersrand (Awarded Faculty Prestigious Post-graduate award 2016)**
PhD Thesis: Clinical and immunological epidemiology of group B streptococcus (GBS) in South Africa
- 2016 **Dr C Cutland, University of the Witwatersrand**
PhD Thesis: Epidemiology and prevention of sepsis in young infants and the potential impact of maternal HIV infection on neonatal sepsis
- 2016 **Dr K Lebogo, University of the Witwatersrand**
PhD Thesis: Pre-clinical evaluation of pneumococcal vaccine candidate molecules in a mouse colonization model
- 2016 **Dr G Naidu, University of the Witwatersrand**
PhD Thesis: Infectious complications in the South African Black child with cancer
- 2016 **Dr M Groome, University of the Witwatersrand (Awarded Faculty Prestigious Post-graduate award 2017)**
PhD Thesis: Rotavirus vaccine and diarrhoeal morbidity in South Africa
- 2016 **Dr G Kwatra, University of the Witwatersrand**
PhD Thesis: Determining immunological correlates of protection against Group B streptococcus colonization in pregnant women
- 2017 **Dr A Malherbe, University of the Witwatersrand**
PhD Thesis: Cell-Mediated and humoral immune responses to trivalent inactivated influenza vaccine in high-risk groups
- 2017 **Dr C Olwage, University of the Witwatersrand**
PhD Thesis: Molecular investigation on the impact of the pneumococcal polysaccharide-protein conjugates vaccine (PCV) on bacterial nasopharyngeal colonization in children
- 2017 **Dr S Dzanibe, University of the Witwatersrand**
PhD Thesis: Natural induced antibodies against Group B streptococcus surface proteins and capsular polysaccharides
- 2017 **Dr O Simani, University of the Witwatersrand**
PhD Thesis: Effects of human immunodeficiency virus infection and treatment with antiretroviral therapy of immunological responses to childhood vaccines
- 2017 **Dr V Baillie, University of the Witwatersrand**
PhD Thesis: Clinical and molecular epidemiology of human rhinoviruses in low to middle income countries
- 2017 **Dr N Mahommed, University of the Witwatersrand**
PhD Thesis: Dignosis utility of Chest X-rays in childhood community pneumonia in the era of bacterial conjugate vaccines, antiretroviral therapy, molecular dignostics and computer aided dignosis
- 2018 **Dr D Moore, University of the Witwatersrand (Awarded Faculty Prestigious Post-graduate award 2019)**
PhD Thesis: Epidemiology of childhood pneumonia in the era of antiretroviral therapy and bacterial conjugate vaccines
- 2018 **Prof S Velaphi, University of the Witwatersrand**
PhD Thesis: Epidemiology, risk factors and diagnosis of neonatal sepsis
- 2020 **Dr J Pathirana, University of the Witwatersrand**
PhD Thesis: Congenital CMV In A High HIV Prevalent Setting, South Africa
- 2020 **Dr E Alexandra Marie Louise Mutsaerts (Awarded Faculty Prestigious Post-graduate award 2020)**
PhD Thesis: Safety and immunogenicity of measles vaccine, varicella vaccine and Hepatitis-A vaccine

- in HIV-exposed and HIV-unexposed South African children.
- 2021** **Dr Y Agosti, University of the Witwatersrand**
PhD Thesis: Epidemiology and sero-correlates of protection of respiratory syncytial virus disease in South African children.
- Current** **Ms S Lukhele, University of the Witwatersrand**
PhD Thesis: Genetic characterization of Group B Streptococcus among colonizing and invasive disease isolates in South Africa
- Current** **DR H Ali, University of the Witwatersrand (Part-time; 2014)**
PhD Thesis: Epidemiology of uveitis and diagnosis of tuberculosis in setting of high HIV prevalence.
- Current** **Dr J Moyes, University of the Witwatersrand**
PhD Thesis: The epidemiology, burden and cost of respiratory syncytial virus in South Africa
- Current** **Dr N Soofie, University of the Witwatersrand**
PhD Thesis: Epidemiology of pertussis infections in South Africa
- Current** **Dr H Moultrie, University of the Witwatersrand**
PhD Thesis: Spatio-temporal distribution of microbiologically-confirmed tuberculosis in South Africa, 2010-2015
- Current** **Dr C Verwey, University of the Witwatersrand**
PhD Thesis: Long-term pulmonary sequelae of Respiratory Syncytial Virus lower respiratory tract infection in children.
- Current** **Ms L Ramocha, University of the Witwatersrand**
PhD Thesis: Epidemiology and pulmonary sequelae development in children with human metapneumovirus
- Current** **Ms S Downs, University of the Witwatersrand**
PhD Thesis: Temporal changes in *Streptococcus pneumoniae* colonization in children and adults following routine childhood immunization with pneumococcal conjugate vaccine in South Africa.
- Current** **Mr T Matuvhunye -University of Witwatersrand**
PhD thesis: Molecular characterization of Group b streptococcus and its association with vaginal microbiome among pregnant women from low-middle income countries.
- Current** **Ms M. S Blose, University of the Witwatersrand**
PhD Thesis: Effect of HIV-1 Exposure and HIV-1 Infection on Persistence of Immunity against Vaccine Preventable Diseases.
- Current** **Mr S Ndlovu, University of the Witwatersrand**
PhD Thesis: A longitudinal investigation of the maternal vaginal microbiome associated with poor foetal birth outcomes including premature births and stillbirths.
- Current** **Ms C Bokop Fotso, University of the Witwatersrand**
PhD thesis: Sero-epidemiology of Measles, Hepatitis B and Hepatitis E among mother-new born dyads in low- and middle-income countries of South Asia and Africa.
- Current** **Ms M Mavhungu, University of the Witwatersrand**
PhD thesis: Association of maternal acquired immunity and Respiratory Syncytial Virus lower respiratory tract infections in infants.
- Current:** **Ms V Gent, University of the Witwatersrand**
PhD thesis: Evaluation of Group B Streptococcus proteins as maternal vaccine candidates.
- Current** **Ms TR Jeché University of the Witwatersrand**
MSc Dissertation : Utility of real-time PCR(Fluidigm) for serotype-specific characterization of *Streptococcus pneumoniae* in adults hospitalized with pneumonia
- Current** **Ms MTM Ramatsebe, University of the Witwatersrand**
PhD Thesis: Molecular evaluation of the association of the vaginal microbiome and adverse pregnancy outcomes in South Africa
- Current** **Mr B Shabangu, University of the Witwatersrand**
PhD Thesis: Genomic characterisation of *Acinetobacter baumannii* associated with neonatal sepsis and stillbirths in a South Africa population
- Current** **Mr William McMacMahon**
PhD Thesis: SARS-CoV-2-specific cell-mediated immunity in naturally infected individuals and in COVID-19 vaccinated individuals with and without HIV
- Current** **Dr Carmen Briner**
PhD Thesis: Understanding The Causes And Factors Contributing To Stillbirths In South Africa And Whether Or Not Minimally Invasive Tissue Sampling Can Be Used As A Diagnostic Tool To More Accurately Determine Cause Of Death And Classify Stillbirths.
- Current** **Dr Fikile Mabena**
PhD Thesis: Epidemiology of community and hospital-acquired invasive infections in young infants

INVITED TALKS – INTERNATIONAL SCIENTIFIC MEETINGS

1. Impact of HIV-1 infection on invasive pneumococcal disease in children *1st International Symposium on Pneumococci and Pneumococcal Disease- Copenhagen, Denmark, 1999: (Oral2-14:45).*
2. Potential impact of pneumococcal conjugate vaccines on *Streptococcus pneumoniae* antibiotic resistance. *European Conference on Antimicrobials, Venice, Italy 2000.*
3. Impact of HIV-1 infection on invasive Pneumococcal disease. *2nd World Society of Paediatric Infectious Disease Conference. Manila, Philippines, November 2000.*
4. HIV-1 infection and invasive pneumococcal disease in children. *2nd International Symposium on Pneumococci and Pneumococcal Disease- Sun City, Northern Province, South Africa, March 2001.*
5. Prevention and treatment of bacterial and *Pneumocystis carinii* pneumonia. *NIH forum, Research for HIV/AIDS Care, Gaborone, Botswana, March 25-29, 2001.*
6. Pneumococcal Conjugate Vaccines: Potential to Interrupt Transmission of Disease. *SEIMC, Madrid, Spain May 2001.*
7. Advances in the prevention of respiratory virus related illness *Infectious Disease Congress of Southern Africa, Cape Town, South Africa, 2-6 December 2001. . (W 4.6).*
8. Can herd immunity jeopardise a randomised-placebo controlled vaccine trial. *3rd International Symposium on Pneumococci and Pneumococcal Diseases, Anchorage, Alaska, USA. May 5-8 2002.*
9. Practical measures in evaluating the cost-effectiveness of a pneumococcal conjugate trial in South African children. *3rd International Symposium on Pneumococci and Pneumococcal Diseases, Anchorage, Alaska, USA. May 5-8 2002.*
10. Epidemiology of invasive Hib disease in sub-Saharan Africa and prospects for intervention with the Hib conjugate vaccine. *World Health Organisation and Partners. Introduction of new vaccines (HepB and Hib) into immunisation programmes. Centurion (Pretoria), South Africa. May 27-28 2002.*
11. Viral pneumonia in HIV-1 infected children. *33rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease. Montreal, Canada, 6-10 October 2002. (S19)*
12. Standardisation of chest radiographs: measuring vaccine efficacy against pneumonia *33rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease. Montreal, Canada, 6-10 October 2002.*
13. *Tuberculosis and Lung Disease. Montreal, Canada, 6-10 October 2002.*
14. Co-Chair and invited speaker: Impact of HIV-1 infection on pneumonia in children. *23rd International Congress of Chemotherapy, Durban, South Africa, June 2003.*
15. A pneumococcal conjugate vaccine to prevent pneumonia in developing countries. *23rd International Congress of Chemotherapy, Durban, South Africa, June 2003.*
16. The pneumococcus and vaccination- where are we in 2004?: Expectations from Countries with high rates of antibiotic resistance beyond the USA. *11th International Congress on Infectious Diseases, Cancun, Mexico, March 4- 7, 2004. (45.004)*
17. Understanding community-acquired bacterial pneumonia in children: Challenges to diagnosing pneumonia in children. *11th International Congress on Infectious Diseases, Cancun, Mexico, March 4-7*

2004. (52:001).
18. Follow-up data from the South African pneumococcal conjugate vaccine trial. *4th International Symposium on Pneumococci and Pneumococcal Diseases, Helsinki, Finland, May 9-13 2004.*
 19. HIV and Bacterial pneumonia: Diagnosis and Prevention. *35th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease. Paris, France 28 Oct-1st Nov 2004.*
 20. Bacterial Pneumonia- do current diagnostic definitions (chest-radiograph alveolar consolidation) cover the full spectrum prevented by vaccination. *5th International Symposium on Pneumococci and Pneumococcal Diseases. Alice Springs, Australia; 2-6 April 2006. (SY3.09)*
 21. Pneumococcal co-infections in Viral associated Pneumonia. *24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Basel, Switzerland May 3-5 2006. (ESPID Young Investigators Award Invitation Presentation).*
 22. Tuberculosis: Recognition and Management in Children with and Without HIV. *12th International Congress on Infectious Diseases. Lisbon, Portugal June 15-18 2006. Session 73.002*
 23. Pneumococcal Diseases and HIV infection in adults and children. *British HIV Association Autumn Conference. Queen Elizabeth II Conference Centre; London; 12-13 October 2006. (Symposium)*
 24. Pneumococcal Conjugate Vaccine in Developing Countries: Potential for Addressing the Ignored Epidemic *Keystone Symposia. Challenges of Global vaccine Development. 8-13th October 2007; Cape Town South Africa. (Symposium)*
 25. Bacterial Infections in Africa. *5th World Congress of the World Society for Pediatric Infectious Diseases. Bangkok; Thailand. November 15-18 2007. (Symposium)*
 26. Current Issues in The Epidemiology and Prevention of Childhood Tuberculosis. *5th World Congress of the World Society for Pediatric Infectious Diseases. Bangkok Thailand. November 15-18 2007. (Symposium)*
 27. First Symposium on Pneumococcal Vaccination in the Asia Pacific Region in Seoul, Korea. December 13-14th 2007. Association between Influenza and Increased Risks of Pneumococcal Infections. (Symposium)
 28. Lessons Learnt from The South African and The Gambian Pneumococcal Conjugate Vaccine Trials. (Symposium) *Physicians Academy for Clinical and Management Excellence. 1st Pneumonia Working Group Conference. Seoul; South Korea. 14-15th December 2007.*
 29. Vaccines to prevent pneumonia and improve child survival. *World Health Organisation: Global Action Plan against Pneumonia. Geneva, Switzerland. 25-27th February 2008.*
 30. Pneumonia-A global cause of childhood morbidity and mortality. *Global Masterclass on Childhood Bacterial Respiratory Diseases. Brussels; Belgium: 29-30th March 2008.*
 31. Pneumococcal vaccine efficacy and effectiveness. *Union of National Paediatric Societies and Association. Rustenburg, South Africa. 29-31st May 2008. (Symposium)*
 32. Integration of Hib and pneumococcal vaccine strategies with other aspects of pneumonia control. *6th International Symposium on Pneumococci and Pneumococcal Diseases. Reykjavik, Iceland. 8-12th June 2008.*
 33. Pneumococcal Disease: It's Link to Pandemic Flu and Antibiotic Resistance. *Malaysian Medical Association. 25-27th June 2008. (Plenary)*

34. Roles for *S. pneumoniae* in Pandemic Flu & Virus associated pneumonia. *Thailand Pediatric Infectious Diseases Society. 29th –30th June 2008.* (Plenary)
35. Improving maternal, newborn and child health in Africa: Immunization Programs in Africa. *African Academy of Sciences. 16-17 March 2009, Pretoria, South Africa.* (Invited talk)
36. Evaluations, Innovations and Transitions. Preparing for *S. pneumoniae* vaccine impact evaluation in South Africa. *PneumoADIP and Hib Initiative Surveillance Networks Investigators Meeting: 4-6 March 2009– Johannesburg, South Africa.*
37. HIV and Pneumococcal Disease *4th Regional Pneumococcal Symposium... Johannesburg, South Africa. 2-3rd March 2008.* (Symposium)
38. Handling Pneumonia. *27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Brussels, Belgium, June 9-13, 2009.* (Symposium)
39. Global Reach of Rotarix™: Broad Protection Against Rotavirus Disease In Developed and Developing Territories. *27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Brussels, Belgium, June 9-13, 2009.* (Symposium)
40. Management of HIV infection and Tuberculosis in children. *1st International Workshop on HIV Pediatrics. 17-18 July 2009; Cape Town; South Africa.*(Symposium)
41. Burden of influenza virus illness in sub-Saharan Africa. *6th World Society for Pediatric Infectious Diseases (WSPID). Buenos Aires, Argentina, November 18-22 2009.* (Invited speaker)
42. Issues of opportunistic infections in HIV affected children. *6th World Society for Pediatric Infectious Diseases (WSPID). Buenos Aires, Argentina, November 18-22 2009.* (Plenary)
43. Immunization of the HIV infected child. *6th World Society for Pediatric Infectious Diseases (WSPID). Buenos Aires, Argentina, November 18-22 2009.* (Meet the professor)
44. Current antibiotics and treatment strategies for childhood pneumonia. *26th International Pediatric Association Congress of Pediatrics. Johannesburg, South Africa, Aug 4-9, 2010.* (Invited talk)
45. *Streptococcus pneumoniae*: Expectations for improving child health in industrializing countries. *26th International Pediatric Association Congress of Pediatrics. Johannesburg, South Africa, Aug 4-9, 2010.* (Invited talk)
46. The global burden of paediatric bacterial infectious diseases. *26th International Pediatric Association Congress of Pediatrics. Johannesburg, South Africa, Aug 4-9, 2010.* (Plenary).
47. 9th International Rotavirus Symposium. Rotavirus in immunocompromised infants (HIV/SCID). 2-3 August 2010, Johannesburg, South Africa. (Plenary).
48. Achievements and Challenges in Managing Childhood Pneumonia. *9th International Congress of Tropical Pediatrics. Bangkok, Thailand 18-20 October 2011.* (Symposium)
49. Meet the Professor: Vaccines. *9th International Congress of Tropical Pediatrics. Bangkok, Thailand 18-20 October 2011*
50. Addressing pneumococcal disease – Challenges and Opportunities. *9th International Congress of Tropical Pediatrics. Bangkok, Thailand 18-20 October 2011.* (Plenary)
51. Unraveling the pathogenesis and etiology of pneumonia with pneumococcal conjugate vaccines. *7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), Melbourne, Australia, November 16-19, 2011.*(Symposium)

52. Global burden of severe RSV illness and its sequelae. *7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), Melbourne, Australia, November 16-19, 2011.*(Symposium)
53. State of the Art Lecture: Pneumococcus. *5th Middle East Paediatrics Conference, Dubai, UAE, 3-25 January 2012. (Plenary)*
54. Update on Tuberculosis. *5th Middle East Paediatrics Conference, Dubai, UAE, 3-25 January 2012. (Plenary)*
55. Out of Africa: Lessons learnt and challenges in evaluating the effectiveness of pneumococcal conjugate vaccine. *8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguazu Falls, Brazil. March 11-15, 2012. Abstract 241.*(Symposium)
56. Pentavalent and Hexavalent Combination Vaccines of Today and Tomorrow. *15th International Congress of Infectious Diseases ICID. Bangkok, Thailand, 13-16 June 2012. (Symposium)*
57. Roadmap to MDG4 - is vaccination a major milestone? *14th Asia Pacific Congress of Pediatrics and 4th Asia Pacific Congress of Paediatric Nursing to be held in Kuching from 8-12 September 2012. (Plenary)*
58. Pneumococcal conjugate vaccines and prevention of pneumonia. *14th Asia Pacific Congress of Pediatrics and 4th Asia Pacific Congress of Paediatric Nursing, Kuching, 8-12 September 2012. (Symposium)*
59. DTPa-HBV-IPV/Hib Building on the 10 year heritage. *14th Asia Pacific Congress of Pediatrics and 4th Asia Pacific Congress of Paediatric Nursing, Kuching, 8-12 September 2012. (Symposium)*
60. Meeting the challenges of pneumococcal vaccination in developing countries. *14th Asia Pacific Congress of Pediatrics and 4th Asia Pacific Congress of Paediatric Nursing, Kuching, 8-12 September 2012. (Symposium)*
61. Progress with Immunisation with Pneumococcal and Rotavirus Vaccines in South Africa. *South African Pediatric Association. Polokwane, Limpopo. 22-26 August 2013.*
62. Influenza Efficacy Studies in Low-Middle Income Countries: South Africa. International Meeting on Influenza Vaccine Effectiveness. *3-4 December 2012. International Conference Centre Geneva (CICG), Geneva, Switzerland.*(Plenary)
63. Securing Current Immunization While Introducing New Vaccines. *1st International African Vaccinology Conference. 8-11 November 2012. Lagoon Beach Hotel, Cape Town, South Africa. (Symposium)*
64. How are we doing in South Africa in meeting our Millennium Developmental Goals? *1st International African Vaccinology Conference. 8-11 November 2012. Lagoon Beach Hotel, Cape Town, South Africa. (Plenary)*
65. Vaccine Success Stories: Pneumococcal vaccines. *1st International African Vaccinology Conference. 8-11 November 2012. Lagoon Beach Hotel, Cape Town, South Africa. (Plenary).*
66. Progress and challenges of maternal vaccination in prevention of neonatal infections in developing countries. *8th World Congress of World Society for Pediatric Infectious Diseases. Cape Town, South Africa, Nov 19-22, 2013. (WSPID Symposium)*
67. Protection of pregnant women, neonates and infants by maternal immunization. *Global Vaccine and Immunization Research Forum (GVIRF), Hyatt Regency Bethesda, USA, 4 to 6 March 2014. (Panelist)*

68. Clinical spectrum and complications of childhood pneumonia in the era of bacterial conjugate vaccines. *16th International Congress on Infectious Diseases*. Cape Town, South Africa, April 2-4, 2014. (ICID symposium).
69. The pertussis vaccination timeline – what data do we have in hand? *16th International Congress on Infectious Diseases*. Cape Town, South Africa, April 2-4, 2014. (ICID: GSK symposium).
70. Vaccines' Contribution to Accomplishment of the MDG4 - Reducing under-5 mortality by 2015. *21st Annual Convention. Pediatric Infectious Diseases Society of the Philippines*. February 2014, 5-6. (State of Art Lecture/Plenary)
71. The Dark Knight Rises: Atypical Respiratory Pathogens. *21st Annual Convention. Pediatric Infectious Diseases Society of the Philippines*. February 2014, 5-6. (Meet the Experts Lecture)
72. Pertussis: She is back! What to do? Whole cell OR acellular vaccines? *9th Congresso Paulista de Infectologia*, Bourbon Atibaia/Sao Paulo, Brazil. 21-24 May 2014. (Congress Symposium)
73. Limits and perspectives in the field of immunization: Is this the only solution? *9th Congresso Paulista de Infectologia*, Bourbon Atibaia/Sao Paulo, Brazil. 21-24 May 2014. (Plenary)
74. Clinical spectrum and complications of childhood pneumonia in the era of bacterial conjugate vaccines. *16th International Congress on Infectious Diseases (ICID)*. Cape Town, South Africa. 3-5th April 2014. (Invited speaker).
75. The pertussis vaccination timeline – what data do we have in hand? *16th International Congress on Infectious Diseases (ICID)*. Cape Town, South Africa. 3-5th April 2014. (Invited speaker- GSK Symposium)
76. Impact of paediatric infection on childhood morbidity and mortality. *South African Paediatric Association*. Cape Town, South Africa 11-13th Sept 2014. (Plenary)
77. Preventing infections in neonates and young infants. *South African Paediatric Association*. Cape Town, South Africa. 11-13th Sept 2014. (Plenary)
78. Maternal Immunization: An evolving frontier in protecting young infants which is scheduled during the session, Vaccine development, on Wednesday 16 July 13h30- 15h00. *17th World Congress of Basic and Clinical Pharmacology*. Cape Town, South Africa, 13-18 July 2014. (Invited speaker)
79. Ethics of Vaccine Research involving Pregnant Women in Low-middle income countries. *Conference on Clinical Research in Pregnant Women: Knowledge, Gaps, and Opportunities*. National Institute for Health (USA) (Invited speaker and participant). Washington DC, 28-29 Sept 2014.
80. Maternal immunization for influenza- the evidence. *Bill and Melinda Gates Foundation Maternal Immunization Stakeholder Meeting*. 29-30 January 2015; Berlin, Germany. (Invited speaker)
81. Role of vaccines in making the world a better place for children. *ISN World Congress of Nephrology*. Cape Town, 13-17 March 2015 (Brenner/Dirk Lecture- Invite Plenary Lecture).
82. Maternal vaccination: Hope or hype for improving fetal outcome and health during early infancy. *German Society for Pediatric Infectious Diseases (DGPI) and the German Working Group for Pediatric Immunology (API)*. 23-25 April 2015. (Invited symposium speaker), Freiburg, Germany.
83. Status of viral vaccines to prevent respiratory infections (influenza, RSV). *25th European Society of Clinical Microbiology and Infectious Diseases Congress (ECCMID)*. 25-28 April 2015, Copenhagen Denmark. (Invited symposium speaker).

84. Global overview of maternal immunisation. *6th Federation of Infectious Diseases Society of South Africa (FIDSSA) 2015: Emerging Threats*. 5–8 November 2015, Champagne Sports Resort, Drakensberg, South Africa (Invited plenary).
85. Expanded Program for Immunisation: Successes, challenges and changes. *6th Child Health Priorities Conference*, 3-5 December 2015, Pietermaritzburg, South Africa (Plenary).
86. Group B Streptococcus with emphasis on the public health value of vaccinating pregnant women. Estimating the Public Health Value of Vaccines. *Foundation Merieux Conference Centre*. Annecy, France 5-7 December 2016.
87. Group B Streptococcus vaccine in pregnant women. *10th Vaccine Congress*. 4-7 September 2016. Amsterdam, The Netherlands.
88. Vaccines and Lung Disease. *South African Thoracic Society*. 18-20 August 2016. Indaba Hotel & Conference Centre, Fourways, Johannesburg, South Africa.
89. Problems of defining the etiology of pneumonia (meet the professor session). *10th International Society on Pneumococci and Pneumococcal Diseases*. 26-30 June 2016. Glasgow, Scotland.
90. Indirect impact of pneumococcal conjugate vaccine in low-middle income countries. *10th International Society on Pneumococci and Pneumococcal Diseases*. 26-30 June 2016. Glasgow, Scotland.
91. Maternal vaccination - beyond influenza. *5th South African Immunology Society Conference*. 6-9 March 2016 Glenburn Lodge, Johannesburg, South Africa.
92. Group B streptococcus immunization in pregnancy. *4th International Neonatal & Maternal Immunization Symposium*. Brussels, Belgium 10-12th September 2017.
93. Overview of the landscape of co-infections and co-morbidities in sub-Saharan Africa, European and Developing Country Clinical Trials Partnership (EDCTP) Stakeholder meeting on co-infections and co-morbidities. The Hague, The Netherlands. 13 Sept 2017. (Keynote speaker)
94. Unravelling Specific Causes of Death in Neonates and Stillbirths: Role of Minimal Invasive Tissue Sampling. *2017 Grand Challenges Meeting*. Washington DC, USA. 1-4 Oct 2017.
95. Panelist, Session 4: Controlled Human Influenza Virus Infection Model (CHIVIM) Methods BMGF Convening on the Influenza Human Challenge Modal for Universal Influenza Vaccine Development. 31 May – 1 June 2018.
96. Panelist, Session 5: Increasing Standardization, Access to Critical Materials, and Capacity. BMGF Convening on the Influenza Human Challenge Modal for Universal Influenza Vaccine Development. 31 May – 1 June 2018.
97. Panelist: Meeting of the WHO Product Development for Vaccines Advisory Committee, Geneva, Switzerland. 26-28 June 2018.
98. Panelist: 2018 PD Challenge Workshop: Collaborating to Improve Translational Medicine in Global Health. 25-27 April 2018.
99. Panelist: Global Health Scientific Advisory Committee Annual Meeting. 23-25 April 2018.
100. Co-chair: Root causes of low coverage and under-immunisation in sub-Saharan Africa Symposium. . Academy of Science of South Africa (ASSAf) Crowne Plaza Hotel, Rosebank, Johannesburg, 30 July 2018.

101. Invited speaker: NIHR Global Health Research Group on Preterm Birth prevention and management (PRIME) Close out workshop – Can maternal health vaccination against viral pathogens prevent preterm birth? 2018.
102. Invited speaker: Plenary address. Southern African HIV Clinicians Society Conference, Midrand, Johannesburg. 24-27 October 2018.
103. Keynote: Stillbirths and early neonatal deaths. 38th Conference on Priorities in Perinatal Care in Southern Africa, 12-15 March 2019, Western Cape, South Africa.
104. Keynote: Vaccination during pregnancy. 38th Conference on Priorities in Perinatal Care in Southern Africa, 12-15 March 2019, Western Cape, South Africa.
105. Panelist: 2019 Annual GH Scientific Advisory Committee Meeting. London, UK. 6-9 May 2019.
106. Speaker: Potential and challenges of maternal immunization in preventing adverse fetal outcomes and protecting young infants. Viith Conference of the South African Immunology Society, 18-20 June 2019, Umhlanga, Kwazulu Natal, South Africa.
107. Speaker: 5th ESCMID Vaccines Conference - Bilbao, Spain, September 2019.
108. RSV vaccine (Resvax) efficacy study in pregnant women. Product Development for Vaccines Advisory Committee (PDVAC) Consultation. 26-28 June 2019; WHO Headquarters, Geneva, Switzerland.
109. Invited Speaker: 5th International Neonatal & Maternal Immunization Symposium (INMIS2019). Vancouver, Canada. 15-17 September 2019.
110. Plenary address: *Maternal vaccination in developing countries*, 38th Annual Meeting of the European Society for Paediatric Infectious Diseases Rotterdam, The Netherlands. 25 – 30 May 2020
111. Keynote speaker: Wits Alumni Webinar, Update on COVID-19 and insights into vaccine trials. , Virtual, 29 September 2020.
112. Keynote speaker: Challenges lying ahead with COVID-19 vaccines in South Africa. Academy of Science of South Africa (ASSAf). Virtual, 15 February 2021.
113. Speaker: International workshop on HIV pediatrics, 2021. COVID-19 in Children and Dolutegravir ART Transition in Pediatrics; Situation Report: African COVID-19 Pandemic in Children. 16-17 July 2021.
114. Moderator: Current concerns with childhood vaccine uptake. Effective ways to increase vaccination rates, Executive education from Columbia University and the University of the Witwatersrand. Virtual, 27 September 2021.
115. SARS-Cov-2 immunity and vaccines: insights from large cohorts. 9 July 2021; European Society of Cardiology, online meeting.
116. Speaker: Pandemic preparedness: Lessons from COVID. 29 June 2021; Virtual Keystone Symposia, Innovative vaccine approaches.
117. SARS-CoV-2 (COVID): Successes and Challenges. 1-3 November 2021; West African College of Physicians Annual General and Scientific Meeting 2021.
118. Speaker: VACCINES FOR ALL: The global race between the virus, its variants and the vaccines, 9 July 2021; Centre for Science and Environment (CSE) Webinar.
119. Invited Speaker: 5th National Health Research Conference, Kingdom of eSwatini, Virtual. "COVID-19, an Emerging & Evolving Global Public Health Threat: The Role of Research.", 26 August 2021
120. Invited Speaker: Virtual, IADR Conference, 20-21 October 2021.
121. Invited Speaker: Virtual FIGO Symposium, World Congress of Gynaecology and Obstetrics. 26 October 2021

122. Invited Speaker: Virtual, Launch of New ISPPD Society & Virtual Webinar on Pneumococcus & COVID-19. June 2021
123. Invited Speaker: Virtual, MRF conference, African perspective on Covid impact on meningitis infections. Online, 1-3 November 2021.
124. Carol Baker Lecture; Keynote Speaker: The 2nd International Symposium on *Streptococcus agalactiae*' Disease (ISSAD), 3-5 November 2021.
125. Invited Speaker: Scifest Africa, Enhancing the public trust in COVID-19 vaccination: Progress and challenges in the regulation, administration and rollout of vaccines in South Africa, 9th November 2021.
126. Invited Speaker: Here Be Lungs Conference, Vaccines for COVID-19, Cape Town, South Africa 24-26 November 2021.

INVITED REFEREE to REVIEW ARTICLES FOR THE FOLLOWING JOURNALS

1. American Journal of Infection Control
2. Archive of Diseases In Childhood and Adolescence
3. BMC Infectious Diseases
4. BMC Central
5. Bulletin of World Health Organisation
6. Clinical Infectious Diseases
7. Clinical Microbiology and Infection
8. Clinical Vaccine and Immunology
9. Drugs
10. Epidemiology and Infection
11. Expert Opinion on Pharmacotherapy
12. Expert Review on Vaccines
13. Future Medicine- Paediatric Health
14. Hospital and Infection
15. International Journal of Infectious Diseases
16. Journal of Clinical Virology
17. Journal of Infection
18. Journal of Infectious Diseases
19. Paediatrics
20. Pediatric Drugs
21. Pediatric Pulmonology
22. PlosMedicine
23. PlosOne
24. The Journal of Pediatrics
25. The Lancet
26. The Lancet Infectious Diseases Journal
27. The Lancet Global Health

28. The Lancet Respiratory Medicine
29. The Pediatric Infectious Diseases Journal
30. The Southern African Journal of Epidemiology and Infection
31. Thorax
32. Vaccine

EDITORIAL BOARD MEMBERSHIPS

1. Southern African Journal of Epidemiology and Infection (2011-)
2. PloSOne (Academic editor) 2009-April 2013.
3. BMC Infectious Diseases (Academic editor) 2010-2013
4. Pneumonia (Australia) (2013-)
5. Archive of Diseases In Childhood and Adolescence/ JAMA Pediatrics (2012-2016)
6. Pediatric Infectious Diseases (US) (2013-)
7. Expert Review Vaccines (Academic editor) (2016-)
8. Journal Infectious Diseases (Editorial Advisory Board) (2016-)

GRANT PROPOSALS INVITED REVIEWER

1. Medical Research Council, South Africa
2. GAVI: PneumoADIP; John Hopkins School of Public Health
3. World Health Organisation, Geneva
4. National Research Foundation, South Africa
5. Wellcome Trust, UK.
6. Health Research Council of New Zealand
7. Thrasher Research Trust; United States of America
8. Bill and Melinda Gates Foundation
9. Total Foundation-Institut Pasteur

DATA AND SAEFTY MONITORING BOARDS (Sponsor and role in parenthesis)

1. Yr: 2014-2015: A Phase Ib, Dose-Escalating, Safety and Immunogenicity trial of the novel monovalent Ebola Zaire candidate vaccine, cAd3-EBO Z in Malian adults aged 18-50 years. (CVD, University Maryland; Member).
2. Yr: 2015-2016: A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa. (WHO; Co-Chair)
3. Yr 2017-2019: Porcine free rotavirus vaccine (GSK multiple protocols, member)
 - i. Protocol #: ROTA-081- A phase IIIA, randomized, partially-blind, multi-center study to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine and to evaluate the PCV-free liquid formulation of GSK Biologicals' HRV vaccine as compared to the currently licensed

- lyophilized formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose vaccination in healthy infants starting at age 6-12 weeks.
- ii. ROTA-082- A phase IIIA, partially-blind, randomized, multi-country study to evaluate the immunogenicity and safety of two different potency lots (approximately 105.8 CCID50 per dose and 105.6 CCID50 per dose) of the PCV-free liquid formulation of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine as compared to the licensed lyophilized formulation of GSK Biologicals' HRV vaccine when administered as a two-dose vaccination in infants starting at age 6-12 weeks.
 - iii. ROTA-090- A phase IIIA, randomized, single blind, multi-country study to evaluate the immunogenicity and safety of three doses of Pediarix®, ActHIB® and Prevenar13® when co-administered with the PCV-free liquid formulation of GSK Biologicals' oral live attenuated HRV vaccine as compared to the currently licensed lyophilized formulation of the HRV vaccine in healthy infants 6-12 weeks of age
4. 2018-2019: A Phase 2, Observer-blind, Active-controlled, Randomized Dose-finding Study in Healthy Infants to Assess the Safety, Reactogenicity and Immunogenicity of 3 Dose Levels of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains Compared to Conventional Salk IPV, in a 6, 10 and 14 Weeks of age Immunization Schedule, and Co administered with Diphtheria, Tetanus, Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Pneumococcal Conjugate and Rotavirus Vaccines. (Janssen; Co-Chair)
 5. Yr 2018-2020: The effect of fractional doses of pneumococcal conjugate vaccine (PCV10 and PCV13) on immunogenicity and vaccine-serotype carriage in Kenyan Infants. (LSTMH, Member)
 6. Yr: 2018-2020: CAPRISA 012A - A Phase | Study to determine the Safety and Pharmacokinetics of the Human monoclonal Antibodies, VRC07-523LS and PGT121 administered subcutaneously to HIV negative Adults in South Africa. (CAPRISA; Chair)
 7. Yr 2019- Current: A Phase 3 double-blind, randomized, active comparator-controlled, group-sequential, multinational trial to assess the safety, immunogenicity and efficacy of a trivalent P2-VP8 subunit rotavirus vaccine in prevention of severe rotavirus gastroenteritis in healthy infants (Chair)

CHAPTERS IN BOOKS

1. Handbook of HIV Medicine. Wilson D, Cotton M, Bekker L, Meyers, T, Venter, F, Maartens, G (Editors). 1 st Edition. **Madhi SA**. Immunization of the HIV-infected child. Chapter 37. Pg 316 -322. 2002 & reprint 2003, 2004. Oxford University Press Southern Africa (Cape Town).
2. Disease And Mortality in Sub-saharan Africa. Jamison DT, Feachem RG, Makgoba MW, Bos ER, Baingana FK, Hofman KJ, Rogo KO (Editors). 2 nd Edition; 2006. **Madhi SA** and Klugman KP. Acute Respiratory Infections. Chapter 11. Pgs 149-162. The World Bank, Washington DC.
3. Emerging Infections 7. WM Scheld, DC Hooper, JM Hughes (Eds.). Klugman KP and **Madhi SA**. Conjugate vaccines as probes to define the burden of pneumococcal and Haemophilus influenzae type b pneumonia as well as the role of viruses in the pathogenesis of pneumonia. Chapter 12. Pgs 215-224. 2006. ASM Press, Washington, DC

4. Child health for all. Immunizations. (ed Kibel M, Saloojee H, Westwood T). Oxford University Press, Southern Africa (Pty) Ltd. Chapter 14. Pgs 281 – 294. 4th Edition, 2007. ISBN 978 019 576295 6
5. Pneumococcal vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP and Mäkelä HP (Eds). **Madhi SA**, Pelton SI. Epidemiology, diagnosis, and treatment of serious pneumococcal infections in children. Chapter 8. Pg 95-116. ASM Press, Washington, DC. 2008. ISBN 978-1-55581-408-3
6. Pneumococcal vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP and Mäkelä HP (Eds). Klugman KP, Cutts F, Adegbola RA, Black S, **Madhi SA**, O'Brien KL, Santosham M, Shinefield H, Sterne JAC. Meta-analysis of the efficacy of conjugate vaccine against invasive pneumococcal disease. Chapter 21. Pg 317-326. ASM Press, Washington, DC. 2008. ISBN 978-1-55581-408-3
7. Pneumococcal vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP and Mäkelä HP (Eds). **Madhi SA**, Klugman KP. Efficacy and Safety of Conjugate Pneumococcal Vaccine in the Prevention of Pneumonia. Chapter 22. Pg 327-339. ASM Press, Washington, DC. 2008. ISBN 978-1-55581-408-3
8. Coovadia's Paediatric & Child Health. A manual for health professionals in developing countries. DF Wittenberg (ed). **Madhi SA**. Principles of infections in children. Part 5 Pg 283-311. Oxford University Press; Southern Africa. 2009. Sixth Edition. ISBN: 978 0 19 5988437.
9. Coovadia's Paediatric & Child Health. A manual for health professionals in developing countries. DF Wittenberg (ed). **Madhi SA**. Systemic infections. Part 5 Pg 312-334. Oxford University Press; Southern Africa. 2009. Sixth Edition. ISBN: 978 0 19 5988437.
10. Coovadia's Paediatrics & Child Health - A Manual For Health Professionals In Developing Countries (7th Revised edition). Green RJ, (ed.) du Plessis NM and **Madhi SA**. Principles of infection in children. 2014.
11. Coovadia's Paediatrics & Child Health - A Manual For Health Professionals In Developing Countries (7th Revised edition). Green RJ, (ed.) **Madhi SA**. Childhood vaccines. 2014.
12. Coovadia's Paediatrics & Child Health - A Manual For Health Professionals In Developing Countries (7th Revised edition). Green RJ, (ed.) Reubenson G and **Madhi SA**. Systemic infections. 2014.
13. Child Health for All: a Manual for Southern Africa. Westwood T, Saloojee H, Shung-King M, (ed). **Madhi SA**, Saloojee H. Immunisation. Pg 281-294. Cape Town: Oxford University Press, 2021.

PUBLICATIONS

My publications record have been submitted as an appendix to the CV.



Professor Shabir A. Madhi

Dean: Faculty of Health Sciences | University of the Witwatersrand, Johannesburg

Professor of Vaccinology

Director: Vaccines & Infectious Diseases Analytics Research Unit (Wits-VIDA)

Co-Director: African Leadership in Vaccinology Expertise (ALIVE)